Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Unsure which cash back card is right for you? Explore different options based on your spending habits and find your ideal match.
25,821 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
When a member of the texas capital bancshares board makes a sizable purchase, it often prompts questions from investo...
As AI stocks cool, a rotation toward durable, revenue-generating assets accelerates. A new wheel technology startup i...
Prospect Capital offers a striking 20%+ yield, but its long-run performance raises questions. This article lays out a...
EMB holds near the high end of its range as volatility fades, but a shift in the 10-year yield, policy signals, or EM...
Discover how NVIDIA stands at the center of the AI revolution, what to watch in its business, and how to assess the i...
When a CEO optimizes liquidity by selling shares, it sparks questions. This guide dives into xometry's (xmtr) recentl...
Megapari unveils World Cup Pass 2026, offering three pass levels, free bets for task completion, and an automatic gra...
If you’re thinking about buying spacex, you’re not alone. Before you buy, ask three foundational questions that cover...
When the Fed paused, a 72-year-old retired investor moved money from stocks to Treasuries for stability. The plan loo...
Cathie Wood is back in the IPO spotlight. This piece breaks down the three newly public names Ark Invest reportedly a...
When a top executive sells stock, investors want to know if it signals trouble or simply personal planning. This arti...